BLACK WEEKSFlakonai −15% · rinkiniai −10% · kita −5%su koduNemokamas siuntimas Vokietijoje nuo €200

Šis puslapis išverstas automatiškai ir jame gali būti klaidų. Ar lietuvių kalba yra jūsų gimtoji? Mielai sulauksime jūsų atsiliepimų ir pataisymų.Siųsti atsiliepimą

The Peptide Desk The Peptide Desk
Ostarine (MK-2866), produkto nuotrauka
SARMs

Ostarine (MK-2866)

SARMs

  • Siunčiame iš Vokietijos

Užsakymas

Vieneto kaina - Nemokamas siuntimas Vokietijoje nuo 200 € Black Weeks metu
  • DHL su sekimu
  • Diskreti pakuotė

4.6 iš 5 TrustpilotAtsiliepimų: 73

Taip pat ieškoma kaip: Ostarin

Trumpai

Ostarine (MK-2866) skaičiais

Pagrindiniai rodikliai iš mūsų žinyno. Vilkite tašką kreive, kad pamatytumėte, kiek lieka po vienos dozės, pagal skaičiavimą.

Visas žinyno įrašas

How long does it stay in the body?

Share left after one dose, calculated with a half-life of ~24 hours

Half-life ~24 hours
After 48 hours: 25 %
Hour 2450 %Hour 4825 %Hour 7212.5 %Hour 1203.1 %

Simplified model without an absorption phase, half-life from the TPD lexicon.

Half-life

approx.24hours

Class
SARMnon-steroidal
Use
Oraldaily
Sizes
25 mg1 size in the shop

Produktui Ostarine (MK-2866) laboratorinės analizės dar nėra. Balsuoti už taiUžsakykite tyrimą, mes apmokame pusęVisos laboratorinės analizės

Žinios

Viskas apie Ostarine (MK-2866)

FAQ

Dažnai užduodami klausimai

Šaltiniai kiekvienam atsakymui: žinyno įrašas

Dar turite klausimų?

Parašykite mums, mūsų komanda jums padės.

What is ostarine?

Ostarine, also enobosarm or MK-2866, is a non-steroidal modulator of the androgen receptor (SARM). It was developed against muscle wasting and is meant to act mainly in muscle and bone. It is not approved, the highest stage was phase 3.

What did the study in healthy older adults show?

120 men over 60 and postmenopausal women received placebo or one of four levels for 12 weeks. At the higher level fat-free mass rose by 1.3 kg more than on placebo, fat fell by about 0.6 kg and weight stayed the same. Stair climbing got faster and insulin resistance fell by 27.5 percent. Side effects were as frequent as on placebo.

And in cancer patients?

In a phase 2 trial with 159 cancer patients with weight loss median fat-free mass rose by 1.5 kg (lower level) and 1.0 kg (higher level), on placebo by 0.02 kg. According to the trial the most common serious events were not related to the drug.

What happens to blood lipids and hormones?

HDL cholesterol fell by 17 and 27 percent. The binding protein SHBG fell by 61 percent in men and 80 percent in women. Total testosterone fell in men as well. Free testosterone did not change significantly.

What did the highest study dose show?

A trial in 136 women with advanced breast cancer had two levels, the higher at 18 mg per day. After 24 weeks 29 to 32 percent had a clinical benefit (response or stable disease). Serious side effects caused by the drug occurred in 8 and 16 percent, mainly raised liver enzymes, too much calcium in the blood and fatigue.

Are trials still running?

Yes. As of 26 October 2026 a phase 2 trial with 239 participants is running that tests weight and body function on semaglutide. A first trial on this with 168 participants is completed. Two phase 3 trials in lung cancer ended in 2013.

Palyginimai

Kuo skiriasi

Susiję

Susiję produktai